PRESS RELEASE published on 02/14/2024 at 17:15, 1 year 9 months ago IAMGOLD annonce la mise en œuvre du retrait obligatoire des actions ordinaires de EURO Ressources IAMGOLD annonce la mise en œuvre du retrait obligatoire des actions ordinaires de EURO Ressources à compter du 27 février 2024, conformément aux termes de l'offre approuvée par l'AMF. Natixis et Norton Rose Fulbright LLP conseillent IAMGOLD dans cette opération Retrait Obligatoire AMF Natixis EURO Ressources IAMGOLD
PRESS RELEASE published on 02/13/2024 at 15:25, 1 year 9 months ago Communique de presse de IAMGOLD FRANCE S.A.S. du 13 fevrier 2024 IAMGOLD France lance un retrait obligatoire d'EURO Ressources à 3,50 euros par action, conformément aux réglementations de l'AMF, suite à l'offre publique de retrait. Détails et calendrier précis disponibles Retrait Obligatoire AMF IAMGOLD France EURO Ressources Offre Publique De Retrait
Published on 12/05/2025 at 02:35, 4 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 22 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 51 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 31 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 56 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 7 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 7 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
